Third quarter 2018 report
SITC 2018: further analyses of the Phase II study of the combination of monalizumab and cetuximab in head and neck patients show encouraging survival data in both subgroups of IO-naïve and IO-pretreated SCCHN patients
Number of shares and voting rights of Innate Pharma as at November 1, 2018
Clinical data featured as oral presentations at two major upcoming oncology conferences
Innate Pharma strengthens and expands its oncology development collaboration with AstraZeneca
Innate Pharma announces Phase II results from monalizumab and cetuximab combination in head and neck cancer at the ESMO 2018 Congress
Innate Pharma announces data presentations on monalizumab at the European Society for Medical Oncology annual meeting 2018
Innate Pharma reports IPH4102 results in advanced Cutaneous T Cell Lymphoma (CTCL)
Innate Pharma reports first half 2018 financial results and business update
Innate pharma announces enrollment of first patient in the Phase I study of IPH5401 in combination with durvalumab (Imfinzi®) in solid tumors
